Foghorn Therapeutics (FHTX) Shares Outstanding (Diluted Average) (2020 - 2025)
Foghorn Therapeutics has reported Shares Outstanding (Diluted Average) over the past 6 years, most recently at $63.0 million for Q4 2025.
- Quarterly results put Shares Outstanding (Diluted Average) at $63.0 million for Q4 2025, up 14.72% from a year ago — trailing twelve months through Dec 2025 was $63.0 million (up 14.72% YoY), and the annual figure for FY2025 was $63.0 million, up 14.72%.
- Shares Outstanding (Diluted Average) for Q4 2025 was $63.0 million at Foghorn Therapeutics, roughly flat from $63.0 million in the prior quarter.
- Over the last five years, Shares Outstanding (Diluted Average) for FHTX hit a ceiling of $63.0 million in Q3 2025 and a floor of $36.8 million in Q1 2021.
- Median Shares Outstanding (Diluted Average) over the past 5 years was $41.9 million (2023), compared with a mean of $47.2 million.
- Biggest five-year swings in Shares Outstanding (Diluted Average): skyrocketed 579.99% in 2021 and later rose 0.68% in 2025.
- Foghorn Therapeutics' Shares Outstanding (Diluted Average) stood at $37.2 million in 2021, then rose by 11.89% to $41.6 million in 2022, then increased by 0.92% to $42.0 million in 2023, then soared by 30.79% to $54.9 million in 2024, then rose by 14.72% to $63.0 million in 2025.
- The last three reported values for Shares Outstanding (Diluted Average) were $63.0 million (Q4 2025), $63.0 million (Q3 2025), and $62.9 million (Q2 2025) per Business Quant data.